

Securities Identification Code: 8086

June 5, 2024

NIPRO CORPORATION

3-26, Senriokashinmachi, Settsu, Osaka Prefecture
Yoshihiko Sano, President and Representative Director

Notice of the 71st Annual General Meeting of Shareholders

Dear Shareholders,

You are cordially invited to attend the 71st Annual General Meeting of Shareholders of NIPRO CORPORATION (the “Company”). The meeting will be held for the purposes described below.

In convening this General Meeting of Shareholders, as the “Company” has taken measures to provide the information contained in the Reference Documents for the General Meeting of Shareholders, etc. (matters for electronic provision) electronically and posted them on each of the following websites on the Internet, please kindly visit any of the below websites and confirm the details.

[the “Company” website]

<https://www.nipro.co.jp/en/ir/stock/meeting.html>

[Website for the materials for the general meeting of shareholders]

<https://d.sokai.jp/8086/teiji/> (Japanese text only)

[Tokyo Stock Exchange website (TSE listed company information service)]

<https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show>

If you are unable to attend the meeting, please review the Reference Documents for the General Meeting of Shareholders as described below and exercise your voting rights via the Internet in accordance with the instructions on page 3, "Guidance on the Exercise of Voting Rights via the Internet", or in writing (by mail) by 5:00 p.m. on Tuesday, June 25, 2024.

In addition, please be kindly advised that this general meeting will be simultaneously live-streamed on the Internet. For further details, please refer to the enclosed "Information on the 71th Ordinary General Meeting of Shareholders". (Please note that you will not be able to participate in the resolutions via the live streaming.)

1. Date and Time: 10:00 a.m. on Wednesday, June 26, 2024

2. Place of meeting: NIPRO HEAD OFFICE HALL
3-26, Senriokashinmachi, Settsu, Osaka Prefecture, JAPAN

3. Meeting Agenda

<Reports>

1. Business report, consolidated financial statements, and report by the independent auditing firm and council of statutory auditors on the Company consolidated financial statements for fiscal 2023 (the 71st business year of the Company) from April 1, 2023 to March 31, 2024.
2. Report of financial statements for fiscal 2023 (the 71st business year of the Company) from April 1, 2023 to March 31, 2024

<Resolutions>

- Agenda No. 1** Appropriation of Surplus
Agenda No. 2 Partial Amendments to the Articles of Incorporation
Agenda No. 3 Election of Eighteen (18) Directors
Agenda No. 4 Election of One (1) Substitute Audit & Supervisory Board Member

4. Decisions upon convocation (Guidance on the exercise of voting rights)

1. If there is no indication of approval or disapproval of a proposal on the voting form when voting rights are exercised in writing (by mail), it shall be deemed that the approval of the proposal has been indicated.
 2. If you exercise your voting rights via the internet or in writing, the online vote will be counted as the valid vote.
 3. If you exercise your voting rights multiple times via the internet, the last online vote will be deemed to be the valid exercise of your voting rights.
 4. If a person who has exercised his/her voting rights in advance via the internet or in writing (by mail) attends the General Meeting of Shareholders, such prior exercise of voting rights shall be deemed to have been withdrawn.
 5. Please refer to page 3 for details on exercising voting rights.
- When attending the meeting, please bring the enclosed Voting Rights Exercise Form and submit it at the reception desk.
- Shareholders who have made a request for delivery of the document will also receive a document stating the matters to be provided electronically although such a document will exclude the matters listed below in accordance with laws and regulations and Article 16 of the Articles of the "Company".
- (i) summary of the system to ensure the appropriateness of business operations in the business report and the operation status of the system
 - (ii) consolidated statement of changes in equity in consolidated financial statements
 - (iii) notes to consolidated financial statements
 - (iv) non-consolidated statement of changes in equity in non-consolidated financial statements
 - (v) notes to non-consolidated financial statements
- Therefore, the business report, consolidated financial statements and non-consolidated financial statements included in this document are a part of the subject documents that were audited by the Accounting Auditor in preparing the Accounting Audit Report and by the Audit & Supervisory Board Members in preparing their audit report.
- In the event of any change in matters for electronic provision, the changes will be posted on each website on the Internet listed on page 1, together with the items before and after the change.
- The reason for having decided to hold this meeting at a location significantly distant from the place where it used to be held in the past, is that we thought it would be more convenient for our shareholders to hold the meeting in a large hall in the head office building, which was installed along with the Company's relocation of its head office from Osaka to Settsu, Osaka Prefecture, as of October 1, 2023.

Guidance on the Exercise of Voting Rights via the Internet

Procedures to vote by entering your voting rights exercise code and password

<https://soukai.mizuho-tb.co.jp/>

- (i) Please visit the website at <https://soukai.mizuho-tb.co.jp/>
- (ii) Please enter the "voting rights exercise code" provided on the voting rights exercise form.
- (iii) Please enter the "password" provided on the voting rights exercise form.
- (iv) After completing the above procedures, please exercise your voting rights in accordance with the instructions on the screen.

Procedure to vote by scanning the QR code

You may also access to website for the exercise of your voting rights without entering the voting rights exercise code and the password.

- (i) Scan the QR code shown on the voting rights exercise form.
(*The QR code is the registered trademark of Denso Wave Incorporated)
- (ii) Please exercise your voting rights by the following instructions on the screen.
You may exercise your voting rights via QR code only once. If you wish to change your vote, please access to the website for PC and enter the "voting rights exercise code" and the "password" provided on the voting rights exercise form in order to re-exercise your voting rights. (*If you re-scan the QR code, you will move to the website for PC.)

If there is anything unclear about how to operate your PC or other devices regarding the exercise of your voting rights, please contact the followings.

Mizuho Trust & Banking Stock Transfer Agency Department Internet help dial: 0120-768-524
(Reception hours: 9:00-21:00, excluding New Year holidays)

For Institutional investors,
"Electronic Voting Platform for Institutional Investors" operated by ICJ Co., Ltd is also available for Institutional Investors.

Reference Documents for Annual General Meeting of Shareholders

Matters to be resolved and relevant information

Proposal No. 1 Appropriation of Surplus

The Company has a business policy that emphasizes distribution of profit to shareholders. The Company endeavors, from a long-range perspective, to strengthen the structure of the development, production and sales departments, with the aim of improving the profitability of its businesses. At the same time, the Company employs a rational profit distribution system, under which profit is distributed on the basis of the operational results for the year.

At this term, we take into consideration the balance of surplus and inside reservation fund with checking the future's business development and our fund's demand on the basis of the above-mentioned policy, and thus we propose year-end dividends as follows:

Year-end dividends

(1) Type of dividend property : Cash

(2) Allotment of dividend property to shareholders, and total amount:

15.00 JPY per common share of the Company stock

Total amount: 2,455,436,355 JPY

Combined with the interim dividends of 10.00 JPY per share already paid, the annual dividend for the year ended March 31, 2024 will be 25 JPY per share.

(3) Effective date of dividends of surplus : June 27, 2024

Proposal No. 2: Partial Amendments to the Articles of Incorporation

1. Reasons for the proposal

In order to clarify the management responsibilities of directors, build a management system that can respond quickly and flexibly to changes in the business environment, and increase opportunities for shareholders to vote their confidence, we have the term of office for directors to change from the current two years to one year.

2. Details of the amendments

Details of the amendments are as follows: (Underlined parts indicate amendments.)

Current Articles of Incorporation	Proposed Amendments
(Term of Office) Article 21. The term of office of Directors shall expire at the conclusion of the ordinary general meeting of shareholders relating to the last fiscal year ending within <u>two years</u> after their election.	(Term of Office) Article 21. The term of office of Directors shall expire at the conclusion of the ordinary general meeting of shareholders relating to the last fiscal year ending within <u>one year</u> after their election.
2. The term of office of a director appointed as a substitute shall expire when the term of office of the retiring director expires.	2. (Deleted)
3. The term of office of a director appointed due to an increase in the number of directors shall expire at the end of the term of office of the other directors.	3. (Deleted)

Proposal No. 3: Election of Eighteen (18) Directors

The terms of office of the all (18) directors will expire, and three (3) directors, Mr. Katsunobu Hashimoto, Mr. Hidehiko Kawazu and Ms. Kiyomi Aoyama will retire from their positions upon that expiration at the conclusion of this Annual General Meeting of Shareholders.

Therefore, the Company proposes the election of eighteen (18) directors, including six (6) outside directors (three of them are newly appointed).

The candidates of directors are as follows.

If this proposal is approved and each candidate assumes office as a director, the ratio of outside directors to all directors will remain one-third.

Name (Date of birth)	Career Summary, Positions, Responsibilities and Significant Concurrent Positions	Number of Shares of the Company Held
<p>1</p> <p>Yoshihiko Sano (January 16, 1945)</p> <p>Reappointment</p>	<p>Nov. 1975 Joined the Company</p> <p>Feb. 1993 Director and Deputy General Manager of Marketing Division of the same company</p> <p>Jun. 2000 Director and General Manager of Marketing Division of the same company</p> <p>Jun. 2000 Director of the Company</p> <p>Apr. 2001 Director and Deputy General Manager of Domestic Division of the Company</p> <p>Jun. 2006 Managing Director and General Manager of Domestic Division of the Company</p> <p>May. 2012 President and Representative Director and General Manager of Domestic Division of the Company</p> <p>Jun. 2012 President and Representative Director and General Manager of Material Division of the Company</p> <p>Oct. 2012 President and Representative Director of the Company (Incumbent)</p> <p>●The reason to be a candidate for directors</p> <p>He was appointed to President and Representative Director of our company in May 2012 through the wealthy experience in the fields of technical sales and marketing of medical equipment. Since then, he has consistently promoted the global expansion of our business and led the improvement of the quality of our products to enhance our brand image and lead the expansion of our group's business performance. As it is expected that his experience and contribution to business performance will continue to contribute to the decision-making of the Company's Board of Directors, as well as to the global expansion of the Company's business and the improvement of its corporate value, he is nominated to be a candidate for directors.</p>	<p>110,745 Shares</p>

2	<p>Kiyotaka Yoshioka (April 29, 1953)</p> <p>Reappointment</p>	<p>Apr. 1976 Joined the Company</p> <p>Feb. 1993 Manager of Nagoya Branch Office of the same company</p> <p>Jun. 1997 Manager of 2nd Tokyo Branch Office of the same company</p> <p>Apr. 2003 General Manager of Kanto Marketing Department of Domestic Division of the Company</p> <p>Oct. 2003 General Manager of Tokyo Metropolitan Area Marketing Department of Domestic Division of the Company</p> <p>Jun. 2006 Director and General Manager of Marketing Department of Domestic Division of the Company</p> <p>Jun. 2012 Managing Director and General Manager of Domestic Division of the Company</p> <p>Feb. 2013 Managing Director and General Manager of Domestic Division and Chief of Business Strategy Office of the Company</p> <p>Jul. 2023 Senior Managing Director and General Manager of Domestic Division and Chief of Business Strategy Office of the Company</p> <p>Apr. 2024 Senior Managing Director and General Manager of Domestic Division (Incumbent)</p>	<p>10,000 Shares</p>
		<p>●The reason to be a candidate for directors</p> <p>He has been involved in our management in light of the wealth of business experience, etc. in the marketing and sales areas of our medical equipment. He also makes progress in the performance of the domestic sales of medical equipment, and plays an important role in our management. As it is expected that his experience and contribution to business performance will continue to contribute to the decision-making of the Company's Board of Directors, as well as to the global expansion of the Company's business and the improvement of its corporate value, he is nominated to be a candidate for directors.</p>	

3	<p>Tsuyoshi Yamazaki (March 30, 1968)</p> <p>Reappointment</p>	Apr. 1991	Joined the Company	18,335 Shares
		Feb. 2009	Deputy Manager of NIPRO Brand Sales Department of Global Business Division of the Company	
		Jun. 2009	Director and General Manager of NIPRO Brand Sales Department of Global Business Division of the Company	
		Apr. 2012	Director and General Manager of International Marketing Department of Global Business Division of the Company	
		Jan. 2014	Director and General Manager of Global Strategy Section of Global Business Division of the Company	
		Jul. 2014	Director and General Manager of MP Glass Division of the Company	
		Jan. 2015	Director and General Manager of MP Glass Division and Chief of Global Strategy Office of the Company	
		Apr. 2016	Director and General Manager of Pharma Packaging Division and Chief of Global Strategy Office of the Company	
		Apr. 2018	President and Representative Director of Nipro Europe Group Companies N.V. (Incumbent)	
		Jun. 2018	Managing Director and General Manager of Pharma Packaging Division, Chief of Global Strategy Office of the Company	
		Jun. 2020	Managing Director and General Manager of International Business Division and Global Business Division and in charge of Pharma Packaging Division	
		May. 2021	Managing Director and General Manager of International Business Division and in charge of Pharma Packaging Division	
		Jul. 2023	Senior Managing Director and General Manager of International Business Division and in charge of Pharma Packaging Division (Incumbent)	
<p>(Significant Concurrent Position)</p> <p>President and Representative Director of Nipro Europe Group Companies N.V.</p> <p>●The reason to be a candidate for directors</p> <p>He has been involved in our management in light of the wealth of business experience, etc. in the international sales of medical equipment and container areas. He also contributes to promotion of business expansion and globalization of our company. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>				

4	<p style="text-align: center;">Takehito Yogo (October 28, 1968)</p> <div style="border: 1px solid black; border-radius: 10px; width: fit-content; margin: 10px auto; padding: 2px 10px;">Reappointment</div>	<p>Oct.1996 Joined Ota-Showa Audit firm(present: Ernst & Young Shin Nihon LLC)</p> <p>Apr. 2000 Certified Public Accountants registration</p> <p>Mar. 2004 Chief of Internal Audit office of Goodman Co., ltd</p> <p>Nov. 2004 Chief of Management Planning office of the same company</p> <p>Feb. 2005 Corporate Officer and Chief of Management Planning office of the same company</p> <p>Sep. 2006 Director and General Manager of Management Division of the same company</p> <p>Jan. 2009 Director and General Manager of Management Headquarters and Production Headquarters of the same company</p> <p>Oct. 2009 President and Representative Director of the same company</p> <p>Jun. 2015 Director and Deputy General Manager of Corporate Planning Headquarters and General Manager of Corporate Planning Department of the Company</p> <p>Feb. 2016 Director and General Manager of Corporate Planning Headquarters and General Manager of Corporate Planning Department of the Company</p> <p>Jun. 2018 Managing Director and General Manager of Corporate Planning Headquarters and General Manager of Corporate Planning Department of the Company</p> <p>Apr. 2020 Managing Director and General Manager of Corporate Planning Headquarters of the Company</p> <p>Jul. 2023 Senior Managing Director and General Manager of Corporate Planning Headquarters of the Company</p> <p>Nov. 2023 Senior Managing Director and General Manager of Corporate Planning Headquarters of the Company (Incumbent)</p> <p>●The reason to be a candidate for directors He has been involved in our management in light of the wealth of business experience in the vascular business and of experience as a certified public accountant. He also contributes to promotion of business expansion and globalization of our company. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>	6,978 Shares
---	--	---	--------------

5	Toshiaki Masuda (September 2, 1952) Reappointment	Apr. 1975	Joined the Company	13,755 Shares
		Apr. 2003	General Manager of Dialysis Product Marketing Department, Domestic Division of the Company	
		Jul. 2006	General Manager of Dialysis Product Development and Sales Department and General Manager of High-Performance Product Development and Sales Department of Domestic Division of the Company	
		Apr. 2008	General Manager of Product Development and Sales Headquarters and General Manager of Cardiovascular Surgical Product Development and Sales Department of Domestic Division of the Company	
		Jun. 2008	Director and General Manager of Product Development and Sales Headquarters of Domestic Division of the Company	
		Nov. 2008	Director and General Manager of Product Development and Sales Headquarters of Domestic Division and Chief of Research & Development Institute of Manufacturing Technology/R&D Division of the Company	
		Nov. 2010	Director and General Manager of Product Development and Sales Headquarters of Domestic Division and Chief of Research & Development Institute of the Company	
		Jun. 2012	Managing Director and Chief of Research & Development Institute of the Company	
		Jul. 2014	Managing Director and General Manager of Product Planning Headquarters and Chief of Research & Development Institute of the Company	
		Oct. 2014	Managing Director and General Manager of Medical Technology Division for Planning, Development & Marketing and general Manager of Product Planning Headquarters and Chief of Research & Development Institute of the Company	
		Apr. 2015	Managing Director and General Manager of Medical Technology Division for Planning, Development & Marketing, Manager of Product Planning Headquarters, Chief of Research & Development Institute and General of Surgical Devices Division(SD Division) of the Company	
		Jun. 2015	Managing Director and General Manager of Medical Technology Division for Planning, Development & Marketing, Chief of Research & Development Institute and General Manager of Surgical Devices Division(SD	

		<p>Division) of the Company</p> <p>Jun. 2022 Managing Director and General Manager of Medical Technology Division for Planning, Development & Marketing, Chief of Research & Development Institute and General Manager of Surgical Devices Division(SD Division) of the Company</p> <p>Nov. 2023 Managing Director and General Manager of Medical Technology Division for Planning, Development & Marketing, Chief of Research & Development Institute</p> <p>●The reason to be a Candidate for Directors</p> <p>He has been involved in our management in light of the wealth of business experience, etc. in the medical equipment's product and development areas. He also makes progress in the performance of the medical equipment, and plays an important role in our management. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>	
--	--	---	--

6	<p>Kyoetsu Kobayashi (May 19, 1955)</p> <p>Reappointment</p>	Jan. 1981	Joined Nihon Medical Industries Ltd.	20,474 Shares
		Apr. 1998	General Manager of Manufacturing Department II of Odate Factory of the Company	
		Jul. 1999	General Manager of Manufacturing Department V of Odate Factory of the Company	
		Aug. 2001	General Manager of Manufacturing Department III of Odate Factory of Manufacturing Technology/ R&D Division of the Company	
		Sep. 2003	General Manager of Manufacturing Department I of Odate Factory of Manufacturing Technology/ R&D Division of the Company	
		Apr. 2004	Chief of Odate Factory of Manufacturing Technology/ R&D Division of the Company	
		Jun. 2009	Director and Chief of Odate Factory of Manufacturing Technology/ R&D Division of the Company	
		Nov. 2010	Director and Chief Odate Factory of the Company	
		Apr. 2014	Managing Director and General Manager of Global Production Division and Chief of Odate Factory of the Company	
		Apr. 2022	Managing Director and General Manager of Global Production Division	
Jul. 2023	Managing Director and General Manager of Stable Production & Crisis Management Division (Incumbent)			
		<p>●The reason to be a candidate for directors</p> <p>He has been involved in our management in light of the wealth of business experience, etc. in the medical equipment manufacturing areas. He also makes progress in the performance of the medical equipment, and plays an important role in our management. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>		

7	<p>Kimihito Minoura (October 12, 1972)</p> <p>Reappointment</p>	Apr. 1995	Joined the Company	29,339 Shares
		Apr. 2005	Manager of Accounting & Corporate Planning Department of the Company	
		Jun. 2009	Director and General Manager of Corporate Planning & Coordination Department of the Company	
		Jul. 2014	Director and General Manager of Corporate Planning Department	
		Jun. 2015	Director and General Manager of Corporate Planning Department and General Manager of Product Planning Department of the Company	
		Feb. 2016	Director and General Manager of Product Planning Development of the Company	
		Apr. 2017	Director and General Manager of New Business Development Department of the Company	
		Apr. 2018	Director and General Manager of Cell products Division and General Manager of New Business Development Headquarters of the Company	
		Jun. 2018	Managing Director and General Manager of Cell products Division and General Manager of New Business Development Department of the Company	
		Aug. 2018	Managing Director and General Manager of Regenerative Medicine Department, General Manager of New Business Development Department of the Company	
		Sep. 2022	Managing Director and General Manager of Regenerative Medicine Department, General Manager of New Business Development Department and Business Promotion Department of the Company	
		Apr. 2024	Managing Director and General Manager of Regenerative Medicine Department, General Manager of New Business Development Department, Business Promotion Department and Business Management Department of the Company (Incumbent)	
		<p>●The reason to be a candidate for directors</p> <p>He has been involved in our management not only in light of the wealth of business experience, etc. in the international accounting and finance areas but in product planning areas. He also makes progress in the performance of the medical equipment and plays an important role in our management. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>		

8	Kazuhiko Sano (January 6, 1952) Reappointment	Mar.1974	Joined the Company	17,627 Shares
		Apr.1998	Deputy Manager of 1st Research Department of Research & Development Laboratory of the Company	
		Mar. 2001	General Manager of 1st Research Department of Research & Development Laboratory of the Company	
		Apr. 2001	General Manager of 1st Research Department of Research & Development Laboratory of Manufacturing Development Division of the Company	
		Jun. 2010	Director and General Manager of 1st Research Department of Research & Development Laboratory of Manufacturing Development Division of the Company	
		Nov. 2010	Director and General Manager 1st Research Department of Research & Development Laboratory of the Company	
		Apr. 2013	Director and Chief of Production Technology Center of the Company	
		Apr. 2014	Director and Deputy General Manager of Manufacturing Department, Chief of Production Technology Center of the Company	
		Feb. 2018	Director and Deputy General Manager of Facilities Department, Deputy General Manager of Manufacturing Department, Chief of Production Technology Center of the Company	
		Jun. 2018	Managing Director and Deputy General Manager of Manufacturing Department, Chief of Production Technology Center of the Company	
		Apr. 2019	Managing Director and General Manager of Production Technology Development Department, Chief of Production Technology Center of the Company	
		Jan. 2020	Managing Director and General Manager of Facilities Department, General Manager of Production Technology Development Department, Chief of Production Technology Center, Deputy General Manager of Production Technology Development Department of the Company	
		Sep. 2020	Managing Director and General Manager of Facilities Department, General Manager of Production Technology Development Department, Chief of Production Technology Center of the Company	
Jul. 2023	Managing Director and General Manager of Facilities Department, Chief of Production Technology Center of the Company (Incumbent)			

●The reason to be a candidate for Directors

He has been involved in our management in light of the wealth of business experience, etc. in the development of medical device manufacturing machinery. He also contributes to promotion of business expansion and globalization of our company. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.

9	Kenichi Nishida (January 13, 1970) Reappointment	Apr. 1994	Joined the Company	6,076 Shares
		Apr. 2007	Chief of Research Planning Office of Pharmaceutical Research Laboratory of Manufacturing Development Division of the Company	
		Aug. 2007	Manager of Research Planning Office of Pharmaceutical Research Laboratory of Manufacturing Development Division of the Company	
		Jun. 2010	Director and General Manager of Research Planning Office of Pharmaceutical Research Laboratory of Manufacturing Development Division of the Company	
		Nov. 2010	Director and General Manager of Research Planning Office of Pharmaceutical Research Laboratory of the Company	
		Oct. 2012	Director and General Manager of Pharmaceutical Development Division of Pharmaceutical Department of the Company	
		Jun. 2017	President and Representative Director of Nipro Pharma Corporation (Incumbent)	
		Apr. 2018	Director and General Manager of Pharmaceutical Department and General Manager of Pharmaceutical Development Promotion Division of the Company	
		Jun. 2018	Managing Director and General Manager of Pharmaceutical Department, General Manager of Pharmaceutical Development Promotion Division of the Company	
		Apr. 2021	Managing Director and General Manager of Pharmaceutical Department of the Company	
		Oct. 2021	Managing Director and General Manager of Pharmaceutical Department, General Manager of Research Planning Office of Pharmaceutical Research Laboratory of the Company	
		Jul. 2023	Managing Director and General Manager of Pharmaceutical Department, General Manager of Pharmaceutical Production Management Division, General Manager of Research Planning Office of Pharmaceutical Research Laboratory of the Company	
Oct. 2023	Managing Director and General Manager of Pharmaceutical Department, General Manager of Pharmaceutical Production Management Division of the Company (Incumbent)			

(Significant Concurrent Position)

President and Representative Director of Nipro Pharma Corporation

●The reason to be a candidate for directors

He has been involved in our management in light of the wealth of business experience, etc. in the research and the promotion of planning and development of pharmaceutical products. He also contributes to promotion of business expansion and globalization of our company. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.

10	<p>Yasushi Ohyama (December 14, 1962)</p> <p>Reappointment</p>	Mar. 2003	Joined the Company	
		Apr. 2009	Deputy Manager of Vascular Product Development and Sales Department of the Company	
		Apr. 2011	General Manager of Vascular Product Development and Sales Department of Domestic Division of the Company	
		Feb. 2013	General Manager of Vascular Business Unit Department of Domestic Division of the Company	
		Jun. 2013	Director and General Manager of Vascular Business Unit Department of Domestic Division of the Company	
		Oct. 2014	Director and General Manager of Vascular Business Unit Department of Planning & Development Engineering Division of the Company	
		Apr. 2015	Director and General Manager of Vascular Division of the Company	
		Jun. 2015	President and Representative Director of Goodman Co., Ltd (Incumbent)	
		Apr. 2018	Director and General Manager of Vascular Division, General Manager of Vascular Product Sales & Development Department of the Company	19,869 Shares
		Jun. 2018	Managing Director and General Manager of Vascular Division, General Manager of Vascular Product Sales & Development Department of the Company	
Apr. 2024	Managing Director and General Manager of Vascular Division (Incumbent)			
		<p>(Significant Concurrent Positions)</p> <p>President and Representative Director of Goodman Co., Ltd</p> <p>●The reason to be a candidate for directors</p> <p>He has been involved in our management in light of the wealth of business experience, etc. in the vascular business.</p> <p>He also contributes to promotion of business expansion and globalization of our company.</p> <p>As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>		

11	<p style="text-align: center;">Hideto Nakamura (April 1, 1958)</p> <div style="border: 1px solid black; border-radius: 10px; padding: 5px; width: fit-content; margin: 10px auto;">Reappointment</div>	<p>Apr. 1980 Joined the Company</p> <p>Apr. 2008 Deputy Manager of Human Resources / General Affairs Division of the Company</p> <p>Jun. 2009 Director and General Manager of Human Resources / General Affairs Division of the Company</p> <p>Jul. 2014 Director and General Manager of General Affairs / Human Resources Department, General Manager of Human Resources Division of the Company</p> <p>Apr. 2020 Director and General Manager of General Affairs / Human Resources Department of the Company</p> <p>Aug. 2021 Director and General Manager of General Affairs / Human Resources Department, General Manager of Governance Supervisory Department of the Company (Incumbent)</p> <p>●The reason to be a candidate for directors He has been involved in our management in light of the wealth of business experience, etc. in the human resources and general affairs areas. He also contributes to promotion of business expansion and globalization of our company. As such a wealth of experience and knowledge will continue to contribute to our management in the future, he is nominated to be a candidate for directors.</p>	25,147 Shares
12	<p style="text-align: center;">Toyoshi Yoshida (March 15, 1963)</p> <div style="border: 1px solid black; border-radius: 10px; padding: 5px; width: fit-content; margin: 10px auto;">Reappointment</div>	<p>Apr. 1988 Joined the Company</p> <p>Apr. 2005 Deputy Manager of Quality Control Division of the Company</p> <p>Apr. 2008 General Manager of Quality Control Division of the Company</p> <p>Jun. 2010 Director and General Manager of Quality Control Department of the Company</p> <p>Apr. 2011 Director and General Manager of Quality Assurance Department of the Company</p> <p>Apr. 2019 Director and General Manager of Quality Assurance & Regulatory Compliance Department of the Company (Incumbent)</p> <p>●The reason to be a candidate for directors He has been involved in our management in light of the wealth of business experience, etc. in the area of quality assurance as well as management of pharmaceutical affairs and post-marketing safety. He also contributes to promotion of business expansion and globalization of our company. As such a wealth of experience and knowledge will contribute enough to our management in the future, he is nominated to be a candidate for directors.</p>	15,383 Shares

13	<p>Yoshiko Tanaka (March 28, 1949)</p> <p>Reappointment</p> <p>Outside Director</p> <p>Independence</p>	<p>May. 1983 General Manager of Pharmacy Department of General Incorporated Association Tokushukai (Osaka Head Office)</p> <p>Jun.1997 General Manager of Pharmacy Department and General Manager of Planning Department of General Incorporated Association Tokushukai (Osaka Head Office)</p> <p>Apr.2002 Part-time Lecturer of Kobe Pharmaceutical University</p> <p>Jun.2002 President and Representative Director of Medihope Corporation (Incumbent)</p> <p>Jul.2014 Council member of Kobe Pharmaceutical University</p> <p>●The reason to be a candidate for outside directors and the outline of the expected role</p> <p>She has an excellent insight and wealth of experience gained in the former job. As we can expect her to provide appropriate guidance and supervision for the business administration based on the knowledge and experience as a business owner, she is nominated to be a candidate for outside directors.</p>	4,297 Shares
14	<p>Yoshiko Shimamori (January 15, 1947)</p> <p>Reappointment</p> <p>Outside Director</p> <p>Independence</p>	<p>Apr. 1990 Manager of Nursing Division of Preparatory Office for Toho University Sakura Medical Center</p> <p>Aug. 1990 Manager of Nursing Division of Tokyo Saiseikai Mukojima Hospital</p> <p>Jun. 1999 Executive Officer of Japanese Nursing Association</p> <p>Apr. 2002 Manager of Nursing Division and Assistant to Director of Kyoto University Hospital</p> <p>Apr. 2007 Professor of Keio University Faculty of Nursing And Medical Care</p> <p>Jun. 2010 President of Tokyo Nursing Association</p> <p>Jul. 2016 Professor of Institute for Biomedical Sciences of Iwate Medical University</p> <p>Apr. 2017 Professor and Dean of School of Nursing of Iwate Medical University</p> <p>Apr. 2021 Professor Emeritus and Council member of Iwate Medical University (Incumbent)</p> <p>Jun. 2021 Director of the Company (Incumbent)</p> <p>●The reason to be a candidate for outside directors and the outline of the expected role</p> <p>Although she does not have an experience of company management, she has an experience of positions as a nurse and a university professor and thus she has expertise and professional experience mainly in medical field. As we can expect that her outstanding insight, wealth of experience, and perspective as a healthcare professional shall be utilized in the sustainable growth and business administration of our group, she is nominated to be a candidate for outside directors.</p>	376 Shares

15	<p style="text-align: center;">Toshiaki Hattori (June 3, 1954)</p> <div style="border: 1px solid black; border-radius: 10px; padding: 5px; width: fit-content; margin: 5px auto;">Reappointment</div> <div style="border: 1px solid black; border-radius: 10px; padding: 5px; width: fit-content; margin: 5px auto;">Outside Director</div> <div style="border: 1px solid black; border-radius: 10px; padding: 5px; width: fit-content; margin: 5px auto;">Independence</div>	<p>Jan. 2000 Branch Manager of Kori Branch, Daiwa Bank Ltd. (currently Resona Bank, Ltd.)</p> <p>Mar. 2002 General Manager of Taisho Branch, Resona Bank Ltd.</p> <p>Jun 2004 General Manager of General Affairs Department, Administration Division, Toami Corporation</p> <p>Jun 2006 Director and General Manager of General Affairs Department, Administration Division of the same company</p> <p>Jun 2008 Managing Director and General Manager of Administration Division, General Manager of General Affairs Department of the same company</p> <p>Jun 2012 Managing Director and General Manager of Administration Division, General Manager of General Affairs Department General Manager of Accounting Department of the same company</p> <p>Jun 2020 Retired from Managing Director of the same company</p> <p>Junv2022 Director of the Company (Incumbent)</p> <p>●The reason to be a candidate for outside directors and the outline of the expected role</p> <p>He has excellent insight and a wealth of experience cultivated through his work at financial institutions and key positions in the general affairs and accounting divisions of listed companies. As we can expect him to provide appropriate guidance and supervision of business administration based on his knowledge and experience as a business owner, he is nominated to be a candidate for outside directors.</p>	- shares
----	---	---	----------

<p style="text-align: center;">16</p>	<p style="text-align: center;">Toshikazu Yoshimori (November 8, 1951)</p> <div style="border: 1px solid black; border-radius: 10px; width: 100px; margin: 5px auto; padding: 2px 10px; text-align: center;">New</div> <div style="border: 1px solid black; border-radius: 10px; width: 100px; margin: 5px auto; padding: 2px 10px; text-align: center;">Outside Director</div> <div style="border: 1px solid black; border-radius: 10px; width: 100px; margin: 5px auto; padding: 2px 10px; text-align: center;">Independence</div>	<p>Apr. 1998 Branch Manager of Tsukiji and Tsukishima Branches, Sakura Bank Ltd. (currently Sumitomo Mitsui Banking Corporation)</p> <p>Apr. 2000 Branch Manager of Shinbashi-higashi Branch of the same company</p> <p>Apr. 2002 General Manager of Ginza Corporate Sales Department of the same company</p> <p>Nov. 2002 Director and General Manager of Insurance Department, HORAI Co., Ltd.</p> <p>Dec. 2002 General Manager of Real Estate Business Department of the same company</p> <p>Oct. 2003 Managing Director and General Manager of President's Office, General Manager of Insurance Department of the same company</p> <p>Dec. 2008 Senior Managing Director and Executive officer and General Manager of General Planning Department of the Company</p> <p>Aug. 2012 Senior Managing Director and Executive officer and General Manager of Insurance Department, General Manager of General Planning Department, in charge of Accounting Department and System Office of the Company</p> <p>Dec, 2013 Sdovisor of Muromachi Building Co., Ltd.</p> <p>Oct. 2014 Director of Japan Health Insurance Association</p> <p>Apr. 2015 Committee Member of Central Social Insurance Medical Council</p> <p>Oct. 2021 Member of the Long-Term Care Insurance committee, Member of the Subcommittee on Long-Term Care Benefits, Expert Member of the Council on Social Security</p> <p>●The reason to be a candidate for outside directors and the outline of the expected role</p> <p>He has extensive experience and insight gained from his work at financial institutions, key positions in the business, accounting and systems divisions of publicly listed companies, and advisory positions with the Ministry of Health, Labor and Welfare. As we can expect him to provide appropriate guidance and supervision of business management based on his knowledge and experience as a business manager, he is nominated as a candidate for outside directors.</p>	<p style="text-align: center;">- shares</p>
---------------------------------------	---	--	---

<p style="text-align: center;">17</p>	<p style="text-align: center;">Yasuhiko Imaizumi (September 27, 1956)</p> <div style="text-align: center; border: 1px solid black; padding: 2px; margin: 5px 0;">New</div> <div style="text-align: center; border: 1px solid black; padding: 2px; margin: 5px 0;">Outside Director</div> <div style="text-align: center; border: 1px solid black; padding: 2px; margin: 5px 0;">Independence</div>	<p>Apr. 2008 Executive officer and General Manager of Nagoya Sales Department of Mizuho Corporate Bank, Limited (currently Mizuho Bank, Ltd.)</p> <p>Apr. 2010 Managing Director and Executive Officer in Charge of Sales Department of the same company</p> <p>Apr. 2012 Managing Director and Executive Officer in Charge of Sales Branches of the same company</p> <p>Apr. 2013 Executive Vice President of the Units of Large Business Corporations, Business Corporations and Financial and Public Corporations of Mizuho Financial Group, Inc. Executive Vice President of the Units of Large Business Corporations, Business Corporations and Financial and Public Corporations of Mizuho bank, Ltd. Representative Vice President of the Units of Large Business Corporations, Business Corporations and Financial and Public Corporations of Mizuho Corporate Bank, Limited</p> <p>Jul. 2013 Representative Vice President of the Units of Large Business Corporations, Business Corporations and Financial and Public Corporations of Mizuho Corporate Bank, Limited</p> <p>Apr. 2014 Representative Vice President of Sales of Business Corporations of Mizuho Securities Co., Ltd.</p> <p>Apr. 2016 Executive Chairman of Mizuho Securities Co., Ltd.</p> <p>Jun. 2018 Executive Vice President of NIPPON STEEL KOWA REAL ESTATE CO., LTD.</p> <p>Apr. 2019 President and Representative Director of Director of NIPPON STEEL KOWA REAL ESTATE CO., LTD.</p> <p>Apr. 2023 Director and Executive Advisor of NIPPON STEEL KOWA REAL ESTATE CO., LTD.</p> <p>Jun. 2023 Executive Advisor of NIPPON STEEL KOWA REAL ESTATE CO., LTD. Outside Director of Nippon Seisen Co., Ltd. (Incumbent)</p> <p>(Significant Concurrent Positions)</p> <p>Executive Advisor of NIPPON STEEL KOWA REAL ESTATE CO., LTD. Outside Director of Nippon Seisen Co., Ltd. (Incumbent)</p> <p>●The reason to be a candidate for outside directors and the outline of the expected role</p> <p>He has excellent insight and a wealth of experience cultivated through his work at financial institutions and key positions in the general affairs and accounting divisions of listed companies. As we can expect him to provide appropriate guidance and supervision of business administration based on his knowledge and experience as a business owner, he is nominated to be a candidate for outside directors.</p>	<p style="text-align: center;">- shares</p>
---------------------------------------	--	---	---

18	<p>Yuka Kushida (October 26, 1963)</p> <p>New</p> <p>Outside Director</p> <p>Independence</p>	<p>Mar. 1994 President and Representative Director of Mitsuko Ltd. (currently J MIRAIMEDICAL Co., Ltd.) (Incumbent)</p> <p>Apr. 2004 President and Representative Director of SAKURA CLINICAL RESEARCH Co., Ltd. (Incumbent)</p> <p>Jun. 2013 Director of PharmaCluster Co., Ltd</p> <p>Nov. 2013 Councillor of Social Welfare Corporation Kishokai (Incumbent)</p> <p>Apr. 2019 Councillor of Kyoto Pharmaceutical University (Incumbent)</p> <p>Jan. 2020 Chairman and Representative Director of Leonis Co., Ltd. (Incumbent)</p> <p>Jun. 2021 Executive Vice President of PharmaCluster Co., Ltd (Position to be changed to Director in June 2024)</p> <p>Apr. 2023 Director of Kyoto Pharmaceutical University (Incumbent)</p> <p>(Significant Concurrent Positions)</p> <p>President and Representative Director of J MIRAIMEDICAL Co., Ltd.</p> <p>President and Representative Director of SAKURA CLINICAL RESEARCH Co., Ltd.</p> <p>Chairman and Representative Director of Leonis Co., Ltd.</p> <p>●The reason to be a candidate for outside directors and the outline of the expected role</p> <p>She has excellent insight and a wealth of experience cultivated through many years of managing a dispensing pharmacy group. As we can expect her to provide appropriate guidance and supervision of business administration based on her knowledge and experience as a medical professional, she is nominated to be a candidate for outside directors.</p>	- shares
----	---	---	----------

Notes :

1. There are no special interests between each candidate and the “Company.”
2. The number of the above stocks includes shares held by Stock Ownership Plan of NIPRO as of April 30, 2024.
3. Ms. Yoshiko Tanaka, Ms. Yoshiko Shimamori, Mr. Toshiaki Hattori, Mr. Toshikazu Yoshimori, Mr. Yasuhiko Imaizumi and Ms. Yuka Kushida are the candidates for outside directors.
4. Ms. Yoshiko Tanaka, Ms. Yoshiko Shimamori and Mr. Toshiaki Hattori will have served as outside directors of the “Company” for 10 years, 3 years and 2 years, respectively, at the conclusion of this Ordinary General Meeting of Shareholders.
5. The “Company” has entered into a contract with Ms. Yoshiko Tanaka, Ms. Yoshiko Shimamori, and Mr. Toshiaki Hattori to limit their liability for damages under Article 423, Paragraph 1 of the Companies Act, pursuant to Article 427, Paragraph 1 of the said Act. The maximum amount of liability for damages under such contracts is the minimum liability amount stipulated by law, and the “Company” intends to continue such contracts with Ms. Yoshiko Tanaka, Ms. Yoshiko Shimamori and Mr. Toshiaki Hattori if their reappointment is approved and they assume office. If the appointment of Mr. Toshikazu Yoshimori, Mr. Yasuhiko Imaizumi and Ms. Yuka Kushida is approved and they assume office, the “Company” will enter into an equivalent contract with them as well, setting the maximum amount of liability for

damages as the minimum liability amount stipulated by laws and regulations.

6. The “Company” has concluded a directors' and officers' liability insurance policy with an insurance company, as stipulated in Article 430-3, Paragraph 1 of the Companies Act, and the premiums for the policy are fully borne by the “Company”. The insurance policy will cover compensation for damages and litigation expenses that may arise as a result of the insured directors and officers being held liable for the performance of their duties or being subject to claims in connection with the pursuit of such liabilities. If the appointment of each candidate is approved and they assume office, they will be included in the insured under the insurance policy.
7. As Ms. Yoshiko Tanaka, Ms. Yoshiko Shimamori and Mr. Toshikazu Hattori meet the criteria of the “Company” for determining the independence of outside officers, and also satisfy the requirements for independent officers as stipulated by the Tokyo Stock Exchange, Inc., they will be newly reported as independent officers if their appointments are approved and they assume office. As Mr. Toshikazu Yoshimori, Mr. Yasuhiko Imaizumi, and Ms. Yuka Kushida also satisfy the criteria for determining the independence of outside officers of the “Company” and the requirements for independent officers as stipulated by Tokyo Stock Exchange, Inc., they will also be newly reported as independent officers if their appointments are approved and they assume office.

Proposal No. 4: Election of One (1) Substitute Audit & Supervisory Board Member

The "Company" proposes the election of one (1) Audit & Supervisory Board Members in advance to prepare for the event that the number of Audit & Supervisory Board Members falls below the number required by laws and regulations. The candidate for a substitute Audit & Supervisory Board Member is as follows.

The Company has obtained approval for this proposal from the **Audit & Supervisory Board**.

No.	Name (Date of birth)	Career Summary, Positions, Responsibilities and Significant Concurrent Positions		Number of Shares of the Company Held
1	Motoaki Sano (Apr 21, 1962) <div style="border: 1px solid black; padding: 2px; width: fit-content; margin: 5px auto;">Outside</div> <div style="border: 1px solid black; padding: 2px; width: fit-content; margin: 5px auto;">Independence</div>	Oct. 2009	General Manager of Electronics Dept. of Sakai Co., Ltd. (currently SK Tech Co., Ltd.)	- shares
		Jun. 2017	Director and General Manager of Electronics Dept. of the same company.	
		May. 2022	Resigned from Director and General Manager of Electronics Dept. of the same company.	
		May. 2022	Assistant to General Manager of Electronics Dept. of the same company (present) ●The reason to be a candidate for a substitute Audit & Supervisory Board Member He has an excellent and extensive knowledge and experience in his former career and is expected to provide proper guidance and supervision in the auditing and business management of the Company from an objective standpoint, and has therefore been nominated as a candidate for the position of substitute Audit & Supervisory Board Member.	

Notes :

1. There are no special interests between the candidate and the "Company."
2. Mr. Motoaki Sano is the candidate for a substitute outside Audit & Supervisory Board member.
3. As Mr. Motoaki Sano meets the criteria of the "Company" for determining the independence of outside officers, and also satisfy the requirements for independent officers as stipulated by the Tokyo Stock Exchange, Inc., he will be newly reported as independent officer if the appointment is approved and he assumes office.
4. The "Company" will enter into a contract with Mr. Motoaki Sano to limit his liability for damages under Article 423, Paragraph 1 of the Companies Act, pursuant to Article 427, Paragraph 1 of the said Act. The maximum amount of liability for damages under the said contract is the minimum liability amount stipulated by law if his appointment is approved and he assumes office.
5. The "Company" has concluded a directors' and officers' liability insurance policy with an insurance company, as stipulated in Article 430-3, Paragraph 1 of the Companies Act, and the premiums for the policy are fully borne by the "Company." The insurance policy will cover compensation for damages and litigation expenses that may arise as a result of the insured directors and officers being held liable for the performance of their duties or being subject to claims in connection with the pursuit of such liabilities. If the appointment of Mr. Sano is approved and he assumes office, he will be included in the insured under the insurance policy.